Gerald L. Chan

Gerald L. Chan, Sc.D. has served as a member of LumiraDx’s board of directors since September 2020. Dr. Chan co-founded Morningside, a private investment group with venture, private equity and property investments, in 1986. In his career as a venture investor, he has invested in more than one hundred tech and biotech companies. He has served as a member of the Scientific Advisory Committee of Brigham and Women’s Hospital since 2018, the Global Advisory Council of Harvard University since 2012, the Dean's Board of Advisors of the Harvard T.H. Chan School of Public Health since 2011. He has been a trustee of Scripps Research Institute since 2016. Dr. Chan serves on the board of directors of Apellis Pharmaceuticals, Inc., Stealth BioTherapeutics Corp., LumiraDX Ltd. and Hang Lung Group Limited. He previously chaired the Innovation Advisory Committee of Wellcome Trust from 2016 until 2020. Dr. Chan received his B.S. and M.S. degrees in engineering from the University of California, Los Angeles, and his Master's degree in medical radiological physics and Doctor of Science degree in radiation biology from Harvard University. He did his post-doctoral training at the Dana-Farber Cancer Institute. Dr. Chan was elected to membership in the American Academy of Arts and Sciences in 2017.